GSDMD and central nervous system cancer: Consistent with the results in the TCGA cohort, GSDMD had a higher expression level in glioma tissues compared to the normal control (p = 0.030, Figure 2B), and patients with high levels of GSDMD had shorter OS (p < 0.0001, Figure 2C) in the GSE16011 cohort.